HPV Vaccination Associated With Reduced Risk of Invasive Cervical Cancer
Study authors assessed the relationship between quadrivalent HPV vaccination and risk of invasive cervical cancer and age of vaccination.
Human Papillomavirus
HPV Prevalence Higher in Adults With More Than 5 Lifetime Sexual Partners
Clinicians must consider patient sexual history in the decision-making process for adult HPV vaccination.
HPV Vaccine Toolkit Increases Vaccination Rates in Primary Care
The purpose of this project is to implement and evaluate the effectiveness of the 4 Pillars Practice Transformation Program to increase uptake of the HPV vaccine among pediatric patients.
Extending HPV Vaccination to Age 45 Provides Small Additional Benefit
Extending the current human papillomavirus (HPV) vaccination program to age 45 years is expected to produce small additional reductions in HPV-associated diseases with high additional costs.
Mailing HPV Kits to Underscreened Women Can Up Screening
Mailing human papillomavirus (HPV) kits to underscreened women is associated with increased screening uptake but does not significantly increase precancer detection or treatment.
Most HPV-Linked Cancers Due to Types Targeted by 9vHPV Vaccine
In 2012 to 2016, an estimated 92% of cancers attributable to HPV were due to HPV types targeted by the 9vHPV vaccine.
Educational Intervention Improves HPV Vaccination
Educational interventions delivered in a clinical setting may improve vaccination behaviors.
Inaccurate Parental Reporting of HPV Vaccination Linked to Multilevel Sociodemographic Factors
Parents of racial or ethnic minority adolescents were more likely to inaccurately report HPV vaccination initiation.
Update on the Ethics of Mandating HPV Vaccination
Following diagnosis, 66.2% of women with the disease survive 5 or more years.1 HPV causes the majority of cervical cancer cases.
USPSTF Revisits Whether Annual Cervical Cancer Screening is Necessary
The US Preventive Services Task Force recommends cervical cancer screening with cervical cytology alone every 3 years or screening with high-risk human papillomavirus testing alone every 5 years.
-
Loading...
-
Loading...
